文献速递炎症性肠病

晚期疗法在克罗恩病中按疾病部位实现缓解的疗效:系统综述与Meta分析

Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn's Disease: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-23

该系统综述与Meta分析纳入14项随机对照试验、3139例中重度克罗恩病患者,比较不同晚期疗法按疾病部位诱导临床缓解的疗效。总体晚期疗法对结肠型疗效高于回肠型(OR 4.09 vs 1.80,P<.001);JAK抑制剂仅在孤立结肠型中观察到疗效。

要点

  • 晚期疗法总体对结肠型CD疗效高于回肠型(OR 4.09 vs 1.80,P<.001)。
  • 抗白细胞介素在结肠型与回肠型间疗效差异未达统计学显著(P=.059)。
  • JAK抑制剂仅在孤立结肠型中显示疗效(OR 4.37),回肠型未见疗效(OR 1.01,P<.001)。

核心结论

  • 晚期疗法对回肠型克罗恩病的疗效幅度总体低于孤立结肠型,JAK抑制剂对回肠型疗效尤为有限。
  • 这些结果可能有助于指导治疗选择。

研究设计与样本

  • 系统综述与Meta分析,纳入14项随机对照试验、3139例中重度克罗恩病患者,比较不同晚期疗法与安慰剂诱导临床缓解的疗效,并按疾病部位(孤立结肠型 vs 回肠型,排除回结肠型)分层。
  • 晚期疗法按主要作用机制分为抗白细胞介素、Janus激酶抑制剂(JAK抑制剂)、抗整合素和肿瘤坏死因子(TNF)拮抗剂四类。

主要发现

  • 晚期疗法总体对结肠型CD的疗效高于回肠型(OR 4.09,95%CI 3.02-5.54 vs OR 1.80,95%CI 1.23-2.63;P<.001)。
  • 抗白细胞介素对结肠型疗效高于回肠型但未达统计学显著(OR 4.29,95%CI 2.77-6.64 vs OR 2.31,95%CI 1.44-3.70;P=.059)。
  • 抗整合素在结肠型与回肠型间未见疗效差异(OR 1.79,95%CI 0.55-5.87 vs OR 2.10,95%CI 0.80-5.53;P=.84)。
  • JAK抑制剂仅在孤立结肠型患者中观察到疗效(OR 4.37,95%CI 2.67-7.15),回肠型未见疗效(OR 1.01,95%CI 0.54-1.89;P<.001)。
  • 所有分析的异质性为轻度至中度。

关键数值与推荐

  • 总体晚期疗法 vs 安慰剂:结肠型OR 4.09(95%CI 3.02-5.54),回肠型OR 1.80(95%CI 1.23-2.63),P<.001。
  • 抗白细胞介素:结肠型OR 4.29(95%CI 2.77-6.64),回肠型OR 2.31(95%CI 1.44-3.70),P=.059。
  • 抗整合素:结肠型OR 1.79(95%CI 0.55-5.87),回肠型OR 2.10(95%CI 0.80-5.53),P=.84。
  • JAK抑制剂:结肠型OR 4.37(95%CI 2.67-7.15),回肠型OR 1.01(95%CI 0.54-1.89),P<.001。

临床怎么用

  • 原文结论指出这些结果可能有助于指导治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We compared the efficacy of different advanced therapies by disease location in patients with Crohn's disease (CD) through a systematic review and meta-analysis. METHODS: Through a systematic review, we identified 14 randomized controlled trials in 3139 patients with moderate-to-severe CD who were treated with different advanced therapies vs placebo, and reported efficacy in inducing clinical remission, stratified by disease location (isolated colonic vs ileal disease, excluding ileocolonic disease). We grouped advanced therapies based on the primary mechanism of action: anti-interleukins, Janus kinase inhibitors (JAK inhibitors), anti-integrins, and tumor necrosis factor (TNF) antagonists. We calculated treatment efficacy (drug vs placebo), overall and by drug class, for colonic vs ileal disease. RESULTS: Overall treatment efficacy of advanced therapies vs placebo was higher in patients with colonic (odds ratio [OR], 4.09; 95% confidence interval [CI], 3.02-5.54) vs ileal CD (OR, 1.80; 95% CI, 1.23-2.63; P < .001). By drug class, anti-interleukins demonstrated a higher efficacy in colonic disease (OR, 4.29; 95% CI, 2.77-6.64) vs ileal disease (OR, 2.31; 95% CI, 1.44-3.70; P = .059), whereas no difference in efficacy was observed with anti-integrins (colonic vs ileal: OR, 1.79; 95% CI, 0.55-5.87 vs 2.10; 95% CI, 0.80-5.53; P = .84). For JAK inhibitors, efficacy was observed only in patients with isolated colonic disease (OR, 4.37; 95% CI, 2.67-7.15), but not in ileal disease (OR, 1.01; 95% CI, 0.54-1.89; P < .001). All analyses had minimal to moderate heterogeneity. CONCLUSIONS: The magnitude of efficacy of advanced therapies for ileal CD is generally lower compared with isolated colonic CD, with JAK inhibitors showing particularly limited efficacy for ileal disease. These results may help inform treatment selection.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee HH, Yuan Y, Boland BS, et al. Efficacy of Advanced Therapies in Achieving Remission by Disease Location in Crohn's Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40712715. doi:10.1016/j.cgh.2025.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。